Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

January 26, 2021

Study Completion Date

May 26, 2021

Conditions
Cervical Cancer
Interventions
DRUG

PEG-rhG-CSF

During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.

DRUG

rhG-CSF

Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.

Trial Locations (1)

400030

Chongqing Cancer Hospital, Chongqing

All Listed Sponsors
lead

Chongqing University Cancer Hospital

OTHER

NCT04542356 - Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer | Biotech Hunter | Biotech Hunter